RNAZ · TransCode Therapeutics Inc
United States · RS rating 7 · As of 2026-11-03
| Price | 1.57 USD |
|---|---|
| 1-day change | -3.7% |
| RS rating (overall / 1M / 3M / 12M) | 7 / 34 / 5 / 6 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 22 / 5 / 31 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -13.4% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +87.3% |
| Market cap (USD) | $8.0M |